Rucaparib monotherapy significantly extended PFS compared with placebo as first-line maintenance treatment for women with ovarian cancer, according to topline data from the randomized phase 3 ATHENA-MONO trial.
Researchers observed the benefit in primary efficacy analyses of two molecularly defined subgroups of newly diagnosed women with advanced disease following platinum-based chemotherapy, including those with homologous recombination deficiency (HRD)-positive tumors and the overall intent-to-treat population. Exploratory subgroups of women with HRD-negative and BRCA-mutated tumors also